GBG HOME

St.Gallen International Breast Cancer Conference 2023

29.09.2022

St.Gallen International Breast Cancer Conference 2023

We are very excited to announce that the next 18th St.Gallen International Breast Cancer Conference 2023 will take place from 15 – 18 March 2023 in Vienna/ Austria.

Experts and literally all major breast cancer cooperative groups and centres worldwide, actively engaged in basic and clinical research as well as in clinical management of patients with breast cancer, will again present the latest data, critically reviewed by leading specialists in the field. The conference closes as usual with an update of the widely acknowledged "St. Gallen International Consensus on the optimal primary treatment of individuals with early breast cancer", which will be published only a few months after the conference.

We all look very much forward to be connected again with each other and to meet in Vienna.

News

  • 18.11.2022 Desiree: dose escalation of everolimus published

    Desiree: dose escalation of everolimus published

    We are proud to inform you that our article A multicentre, randomised, double-blind, phase II study to evaluate the tolerability of an induction dose escalation of everolimus in patients with metastatic breast cancer (DESIREE; GBG 86) is now available online.

    Mehr ...
  • 10.11.2022 Deutscher Krebskongress

    Deutscher Krebskongress

    Die GBG ist mit mehreren Postern auf dem 35. Deutschen Krebskongress vom 13. – 16. November 2022 in Berlin vertreten.

    Mehr ...
  • 08.11.2022 GBG research at SABCS 2022

    GBG research at SABCS 2022

    We are proud to present our research at the San Antonio Breast Cancer Symposium, December 6-10

    Mehr ...
  • 14.10.2022 Location of Subcutaneous Trastuzumab Injection

    Location of Subcutaneous Trastuzumab Injection

    Subcutaneous injection of trastuzumab into the thigh versus abdominal wall in patients with HER2-positive early breast cancer: pharmacokinetic, safety and patients´ preference - substudy of the randomised phase III GAIN-2 study

    Mehr ...

GBG Forschungs GmbH
Dornhofstr. 10 | 63263 Neu-Isenburg | Fax +49 6102 7480-440

+49 6102 7480-0 | nfGBGd